Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Companies

Top Ten Companies // Browse A - Z of companies

  • Merck KGaA (Merck)
  • Merck (Merck KGaA)
  • Pfizer
  • Roche
  • Novartis
  • GlaxoSmithKline (GSK)
  • GSK (GlaxoSmithKline)
  • Bristol-Myers Squibb
  • Lilly
  • Bayer

Browse the A - Z of Companies

  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

G

  • Galapagos
  • Galaxy Biotech
  • Galderma
  • Galena BioPharma
  • Galenea Corp
  • Galenica
  • Galenika
  • Galephar Pharmaceutival Research
  • Gambro
  • Gansu Duyiwei
  • Gate Pharmaceuticals
  • GE Healthcare
  • Gedeon Richter
  • Gemin X Pharma
  • Gen-Probe
  • GENEART
  • Genentech
  • GeneraMedix
  • Generex Biotechnology
  • Genesis Biopharma
  • GENETRIX
  • Genfar SA
  • Genfit
  • Genix
  • Genmab
  • Genmed
  • GeNO
  • Genom Biotech
  • Genomma Lab
  • Genoptix
  • Genor BioPharma
  • Genoscience
  • Genta
  • Gentium
  • Genus Pharma
  • GenVec
  • Genzyme
  • Gerolymatos
  • Geron Corp
  • Gerot Lannach
  • Getz Pharma
  • Gilead Sciences
  • Giliad Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Global Vision
  • GlobeImmune
  • Gloucester Pharmaceuticals
  • GlycoMimetics
  • Glycosan BioSystems
  • Glycotope
  • GlycoVaxyn
  • Goldshield
  • GP Pharm
  • Graceway Pharmaceuticals
  • Graffinity Pharmaceuticals
  • Green Cross
  • GREER Laboratories
  • Grifols
  • Grindeks
  • Grumant
  • Grunenthal
  • GSK
  • GTC Biotherapeutics
  • GTx
  • Guangdong BeiKang Pharma
  • Guangzhou BeBetter Medicine Technology
  • Guerbet
  • Guilford Pharmaceuticals
  • GVK Biosciences
  • GW Pharmaceuticals
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS